Jazz Pharmaceuticals (JAZZ) Other Non-Current Liabilities (2012 - 2026)

Jazz Pharmaceuticals has reported Other Non-Current Liabilities for 15 years, with the latest figure at $161.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 77.24% year-over-year to $161.5 million; the trailing twelve-month figure through Mar 2026 stood at $161.5 million (up 77.24% YoY), and the FY2025 full-year result was $124.4 million, up 43.63% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $161.5 million, up from $124.4 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $161.5 million in Q1 2026, with the low at $86.6 million in Q4 2024.
• Average Other Non-Current Liabilities over 5 years is $116.6 million, with a median of $122.7 million recorded in 2023.
• Year-over-year, Other Non-Current Liabilities declined 29.41% in 2024 and surged 77.24% in 2026.
• Tracing JAZZ's Other Non-Current Liabilities over 5 years: stood at $144.0 million in 2022, then fell by 14.78% to $122.7 million in 2023, then slipped by 29.41% to $86.6 million in 2024, then jumped by 43.63% to $124.4 million in 2025, then rose by 29.82% to $161.5 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $161.5 million (Q1 2026), $124.4 million (Q4 2025), and $108.9 million (Q3 2025), per Business Quant data.

Peer Comparison